Back

Disease progression and outcomes in patients with transthyretin amyloid cardiomyopathy receiving tafamidis

20 May 2025 (10:00 - 10:45)
Organised by: Logo
Congress Presentation Part of: Expanding insights from heart failure registries and surveys Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speakers

Photo
Professor Marianna Fontana

University College London, London (United Kingdom of Great Britain & Northern Ireland)

Photo
Doctor Valentina Marino

(Italy)

5 More presentations in this session

Presentation thumbnail
Age-related disparities in heart failure: insights into clinical profiles, treatment gaps, and outcomes from a multi-center and multi-ethnic study
Doctor A. Koh (Kuching, MY)
Abstract Slides Video
Presentation thumbnail
Non-conventional parameters from holter ECG: a promising tool for heart failure risk stratification
Doctor S. Duca (Iasi, RO)
Abstract Slides Video
Presentation thumbnail
The epidemiology of heart failure in Hungary: basic data and temporal trends from the Hungarian nationwide epidemiological study (HF-EPI-HUN) over a 15-year period (2009-2023)
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Evaluating survival outcomes across NT-proBNP levels and introduction of a high alert pathway: an island wide experience
Doctor A. Henry (Oxford, GB)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics, management trends, and outcomes of acute heart failure in Korea: Insights from the SMILE-HF Registry
Associate Professor S. Lee (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Expanding insights from heart failure registries and surveys

The Event

Event poster

Heart Failure 2025

20 May 2025 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Impact of Tafamidis on clinical outcomes in real-world patients with ATTR-CM
thumbnail
Congress Presentation
Improvements in cardiac functional status and health-related quality of life in patients receiving early access tafamidis
thumbnail
Congress Presentation
Outcomes with early access tafamidis in patients with variant transthyretin amyloid cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources